Study of KIV-318 for advanced multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests an investigational drug called KIV-318 for people with multiple myeloma that has come back or not responded to standard treatments. It aims to see if KIV-318 is safe and effective in targeting a protein called BCMA on myeloma cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have multiple myeloma that has come back or not responded to at least 3 previous treatments, including a proteasome inhibitor (like bortezomib) and/or an immunomodulatory drug (like lenalidomide) and/or a CD38 antibody (like daratumumab).
- You must have signs of disease activity, such as a certain level of M-protein in your blood or urine, or high free light chains in your blood.
- Your overall health must be fairly good (able to do most daily activities), and you should have a life expectancy of at least 3 months.
- You must have adequate organ function, including acceptable blood counts, kidney function, and liver function, as checked by tests.
- If you have not received CAR-T or T-cell engager therapy before, you may join one part of the study; if you have, you may join another part if you also test positive for BCMA.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy (KSVCBD) for people with multiple myeloma that has returned or not responded to other treatments. It may help if your cancer cells have certain markers, CD19 or BCMA.
This early-phase trial tests an experimental drug called IMV102 for people with multiple myeloma that has come back or stopped responding to at least 3 prior treatments. The study aims to see if IMV102 is safe and how well it works.
This trial tests a new experimental drug called CM336 for people with multiple myeloma that has come back or stopped responding to standard treatments. The drug may work by helping your immune system attack and destroy myeloma cells. If you join, you will receive the study treatment and be closely monitored to see how well it works and how safe it is.
This trial tests a new CAR-T cell therapy that targets two proteins (BCMA and CD19) on myeloma cells. It may help patients whose myeloma has come back or stopped responding to previous treatments.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
This trial tests a new intravenous treatment, ABBV-438, for adults with multiple myeloma that has returned or not responded to prior therapies. It aims to see if the drug is safe, tolerable, and how it moves through the body.
Hear when a new Relapse and/or Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.